Intrinsic™ Dual Chamber ICD
With MVP™ Mode (Managed Ventricular Pacing)
Clinical Need
The Danish Study, DAVID and MOST Sub-study clinical trials have shown that disrupting normal electrical conduction with unnecessary ventricular pacing can increase the risk of heart failure, atrial fibrillation and death.1,2,3
Clinically Proven MVP Mode in Intrinsic™ DR ICD
- Promotes intrinsic conduction and is clinically proven to reduce unnecessary right ventricular pacing to approximately 4%.4,5
- Provides functional AAI(R) pacing with the safety of dual chamber ventricular support in the presence of transient or persistent loss of AV conduction.6
- Delivers continuous automatic conduction checks by monitoring each heart beat6
- Recognizes when normal conduction is present and returns from DDD(R) to
AAI(R)6
Intrinsic DR ICD
- Performs similarly to Maximo™ DR in terms of short consistent charge times, longevity, and 35J output
- Includes clinically proven PainFREE™ programming7, Enhanced PR Logic® detection8, Leadless™ ECG, and Cardiac Compass® Trends reporting
 |
Click the thumbnail to see |
Cardiac Compass graphically displays a patient’s |
|
In the MVP clinical study5, the Cardiac Compass
report was used to monitor a patients' percent ventricular pacing (%VP).
The patients were randomized to 1 month each in MVP ON and MVP OFF (DDD/R)
mode. The above graph case study that shows with MVP OFF, the %VP was over
90% and when MVP was turned ON the %VP was 4%. When the patient exited
the study, MVP mode was OFF and the original DDD settings were implemented
as the study protocol required. In DDD the %VP again rose significantly.
Cardiac Compass provides information on AF burden and
ventricular rate during AT and AF.
Meeting Clinical Needs
"Based on the MVP clinical trial experience, the reduction in right ventricular pacing achieved with MVP may greatly exceed that which can be achieved with conventional pacing modes," said Michael O. Sweeney, M.D., an electrophysiologist at Brigham and Women's Hospital in Boston and the principal investigator for the MVP clinical trials. "MVP meets a critical need, particularly among our ICD patients with heart failure and reduced ventricular function who are at risk for sudden cardiac arrest, but whose electrical conduction may be normal and require little or no pacing."4
References:
1Anderson H, Nielsen J, Thomsen P, et al. Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick sinus syndrome. Lancet. 1997;350:1210-1216.
2DAVID Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. JAMA. 2002;288(24):3115-3123.
3Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. MOde Selection Trial Investigators. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107(23):2932-2937.
4Sweeney M, Shea J, Fox V, et al. Randomized pilot study of a new atrial-based minimal ventricular pacing mode with dual chamber implantable cardioverter-defibrillators. Heart Rhythm. 2004;1:160-167.
5Mueller M. Medtronic Marquis® MVP Mode Study. April 2004. Data on file.
6Medtronic Intrinsic™ ICD Product Manual.
7Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. 2001;104(7):796–801.
8Willkoff B, Gillberg J, DeSouza C. The Enhanced PR Logic® dual chamber tachyarrhythmia detection algorithm: Retrospective analysis of supraventricular tachycardia with long PR intervals. JACC 2001:Abstract #873-4.